+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 1 Actively Recruiting clinical trials

C

Actively Recruiting

Researchers are evaluating the efficacy and safety of a fixed combination of follitropin alfa and lutropin alfa compared to human menopausal gonadotropin hMG in Japanese women with luteinizing hormone LH and follicle stimulating hormone FSH deficiency undergoing assisted reproductive technology ART. The study focuses on women who are premenopausal and wish to conceive, addressing fertility challenges related to these hormone deficiencies. This is a Phase 3 interventional trial with a randomized, parallel-group design. Participants will be assigned to one of two groups one receiving a fixed combination of recombinant follitropin alfa and lutropin alfa in a 21 ratio, and the other receiving hMG. Both treatments are administered daily by subcutaneous injection during ovarian stimulation, up to 18 days. Additional medications include daily cetrorelix acetate starting on Day 5 or 6 of stimulation to prevent premature ovulation, and coriongonadotropin alfa for final follicular maturation. After oocyte retrieval, participants will self-administer progesterone gel intravaginally for luteal phase support. During the study, participants will undergo assessments such as ultrasound scans to monitor follicle development, hormone level evaluations, and semen analysis of the male partner. Researchers will track the total number of oocytes retrieved, dosage and duration of gonadotropin treatment, embryo development, pregnancy rates, and safety outcomes including adverse events and ovarian hyperstimulation syndrome. The total study duration is about 5.5 months for those not becoming pregnant and up to 13 months for those with confirmed pregnancy.

Age: 18Years - 42YearsFEMALEPhase 3
21 locations